During mammalian development, cells in the developing fetus gradually become more committed to their specifi c lineage. Th e cellular diff erentiation process specializes to achieve a particular biological function in the adult, and the potential to diff erentiate is lost. Cellular diff erentiation has traditionally been thought of as a unidirectional process, during which a totipotent fertilized zygote becomes pluripotent, multipotent, and terminally diff erentiated, losing phenotypic plasticity (Figure 1 ). However, recent cloning experiments using nuclear transplantation have demonstrated that the epigenetic constraints imposed upon diff erentiation in mammalian oocytes can be released and the adult somatic nucleus restored to a totipotent embryonic state [1] . Th is process, a rewinding of the developmental clock, is termed nuclear reprogramming.
During mammalian development, cells in the developing fetus gradually become more committed to their specifi c lineage. Th e cellular diff erentiation process specializes to achieve a particular biological function in the adult, and the potential to diff erentiate is lost. Cellular diff erentiation has traditionally been thought of as a unidirectional process, during which a totipotent fertilized zygote becomes pluripotent, multipotent, and terminally diff erentiated, losing phenotypic plasticity ( Figure 1 ). However, recent cloning experiments using nuclear transplantation have demonstrated that the epigenetic constraints imposed upon diff erentiation in mammalian oocytes can be released and the adult somatic nucleus restored to a totipotent embryonic state [1] . Th is process, a rewinding of the developmental clock, is termed nuclear reprogramming.
Embryonic stem (ES) cells derived from the inner cell mass of the mammalian blastocyst, an early-stage embryo, were fi rst established from mice by Evans and Kaufman in 1981 [2] . Approximately two decades later, a human ES (hES) cell line was established by Th omson and colleagues [3] . ES cells possess a nearly unlimited capacity for self-renewal and pluripotency: the ability to diff erentiate into cells of three germ layers. Th is unique property might be useful to generate a suffi cient amount of any diff erentiated cell type for drug screening or evaluations of drug toxicity and for cell replacement therapy. In addition, pluripotent stem cells provide us with an opportunity to understand early human embry onic development and cellular diff erentiation. Pluripotent ES cells are spun off directly from pre-implantation embryos [2] [3] [4] [5] . To induce the somatic cell back to a pluripotent state, a strategy such as nuclear transplantation is fraught with technical complications and ethical issues. Th us, the direct generation of pluripotent cells without the use of embryonic material has been deemed a more suitable approach that lends itself well to mechanistic analysis and has fewer ethical implications [6] .
In a breakthrough experiment, Takahashi and Yamanaka [7] identifi ed reprogramming factors normally expressed in ES cells, Oct3/4, Sox2, c-Myc, and Klf4, that were suffi cient to reprogram mouse fi broblasts to become pluripotent stem cells closely resembling ES cells. Because they were induced by the expression of defi ned factors, these cells were termed induced pluripotent stem (iPS) cells [7] . Since this landmark report in 2006, the technology has been rapidly confi rmed among a number of species, including humans [8, 9] , rhesus monkeys [10] , rats [11, 12] , rabbits [13] , pigs [14] and two endangered primates [15] . In addition, mouse iPS (miPS) cells can be derived from various cell types, including fi broblasts [7, 16] , neural cells [17, 18] , liver cells [19] , pancreatic β cells [20] , and terminally diff erentiated lymphocytes [21, 22] . Subsequently, human iPS (hiPS) cells have been derived from various readily accessible cell types, including skin fi broblasts [8, 9] , keratinocytes [23] , gingival fi broblasts [24] , peripheral blood cells [25, 26] , cord blood cells [27, 28] and hair follicle cells [29] .
Th ese products and systems for this state-of-the art technology provide useful platforms for disease modeling and drug discovery, and could enable autologous cell transplantation in the future. Given the methodologies for studying disease mechanisms, disease-and patientspecifi c iPS cells can be derived from patients. For applying novel reprogramming technologies to bio medical fi elds, we need to determine the essential features of iPS cells. In this review, we summarize the functional and molecular properties of iPS cells in comparison to ES cells in the undiff erentiated state and with regard to diff erentiation effi ciency. We also review evaluation for the types of diff erentiated cells derived from of iPS and ES cells and compare the functions of these.
Reprogramming methods and factors
Although the establishment of iPS cells from somatic cells is technically easier and simpler compared with nuclear transplantation, several variables should be considered due to variations in the reprogramming process, including the reprogramming factors used, the combinations of factors and the types of donor-parent cells. Each method has advantages and disadvantages, such as effi ciency of reprogramming, safety, and complexity, with the process used aff ecting the quality of the resultant iPS cells. Initial generations of miPS and hiPS cells employed retroviral and lentiviral vectors [7] [8] [9] (Table 1) , carrying the risk of both insertional muta genesis and oncogenesis due to misexpression of the exogenous reprogramming factors, Oct3/4, Sox2, c-Myc, and Klf4. In particular, reactivation of c-Myc increases tumorigenicity in the chimeras and progeny mice, hindering clinical applications.
Since the initial report of iPS cell generation, modifi cations to the reprogramming process have been made in order to decrease the risk of tumorigenicity and increase reprogramming effi ciency [30] [31] [32] . Several small molecules and additional factors have been reported to enhance the reprogramming process and/or functionally replace the role of some of the transcription factors (Table 1) . Small molecules are easy to use and do not result in permanent genome modifi cations, although iPS generation using only a set of small molecules has not been reported. Combining small molecule compounds with reprogramming factors would enhance reprogramming effi ciency. Integration-free hiPS cells have been established using Sendai virus [33, 34] , episomal plasmid vectors [35, 36] , minicircle vectors [37] , and direct protein Retrovirus OSKM Human fi broblasts [8] , mouse fi broblasts [7] , human keratinocytes [23] , human peripheral blood cells [25] Human fi broblasts, adipose stem cells [93] Vitamin C, VPA OSK Adult human dermal fi broblasts [30] Mouse embryonic fi broblasts [94] Wnt3a
Rat liver progenitor cells [11] MEK/ALK5/GSK3b inhibitor Mouse embryonic fi broblasts [93] Vitamin C
Mouse and human fi broblasts [32] GLIS1
Mouse embryonic fi broblasts [95] mmu-miR-106a/18b/20b/19b/92a/363 or 302a/302b/302c/302d/367
Human fi broblasts [96] hsa-miR-302b or 372 OK Mouse embryonic fi broblasts [97] BIX01294, BayK8644
Neonatal human epidermal keratinocytes [98] GSK3b inhibitor O Mouse neural stem cells [99] Mouse fi broblasts [100] GSK3b inhibitor, vitamin C, BMP4
hsa-miRHuman skin cancer cells [101] 
Sendai virus OSKM Human fi broblasts [33] , human cord blood [102] a O, OCT3/4; S, SOX2; K, KLF4; M, C-MYC; M*, L-MYC; N, NANOG; L, LIN28. ALK, anaplastic lymphoma kinase; BayK8644, L-type calcium channel agonist; BIX01294, histone methyltransferase inhibitor; BMP, bone morphogenetic protein; GSK, glycogen synthase kinase; GLIS, GLI (MIM 165220)-related Kruppel-like zinc fi nger; LIF, leukemia inhibitory factor; PDK, pyruvate dehydrogenase kinase; shRNA, short hairpin RNA; siRNA, small interfering RNA; TGFBR, transforming growth factor beta receptor; UTF, undiff erentiated transcription factor; VPA, valproic acid (histone deacetylase inhibitor). [38, 39] or mRNA [40] delivery (Table 1) . However, direct delivery of proteins or RNA requires multiple transfection steps with reprogramming factors compared to other viral integration methods.
iPS cells appear indistinguishable from ES cells
Th e key to generating iPS cells is to revert somatic cells to a pluripotent state that is molecularly and functionally equivalent to ES cells derived from blastocysts (Table 2) . Reprogrammed iPS cells express endogenous transcription factors that are required for self-renewal and maintenance of pluripotency, such as OCT3/4, SOX2, and NANOG, and for unlimited proliferation potential, such as TERT [8, 9] . Telomeres were elongated in iPS cells com pared to the parental diff erentiated cells in both humans and mice [41, 42] . In addition, cellular organelles such as mitochondria within hiPS cells were morphologically and functionally similar to those within ES cells [43] . Th e establishment of an ES cell-like epigenetic state is a critical step during the reprogramming of somatic cells to iPS cells and occurs through activation of endo genous pluripotency related genes. Bisulfi te genomic sequen cing has shown that the promoter regions of the pluripotency markers NANOG and OCT3/4 are significantly demethylated in both hiPS and hES cells [8, 44] , and the heterogeneity of X chromosome inactivation in hiPS cells is similar to that in ES cells [45] . In terms of multilineage diff erentiation capacity, miPS cells from various tissue types have been shown to be competent for germline chimeras [19, 32, 46] . It was shown that miPS cells generated viable mice via tetraploid comple mentation [47, 48] . In the mouse system, iPS cells retain a developmental pluripotency highly similar to that of mouse ES cells according to the most stringent tests. Although it has been generally assumed that autologous cells should be immune-tolerated by the recipient from whom the iPS cells were derived, Zhao and colleagues [49] reported that the transplantation of immature miPS cells induced a T-cell-dependent immune response even in a syngeneic mouse. Th is is an unexpected result but some issues need to be considered: the infl uence of the cell type of origin on the immunogenic properties of resultant iPS cells must be explored; undiff erentiated iPSCs should never be used for medical applications; and the mechanism of aberrant gene expression should be determined [50] .
To functionally assay hiPS cells, teratoma formation and histological analysis to confi rm the presence of structures derived from all three germ layers are currently regarded as the most rigorous ways to prove pluripotency of human stem cells. Recently, Müller and colleagues [51] proposed the use of PluriTest, a bioinformatics assay for the prediction of stem cell pluripotency using microarray data. Such microarray-based gene expression and DNA methylation assays are low cost, save time and have been used to evaluate the diff erentiation effi ciency of individual cell lines [52] . [53] ).
ES and iPS cells diff er in their epigenetic signatures
Genome-wide analyses of histone methylation patterns have demonstrated that iPS cells were clearly distinguished from their origin and similar to ES cells in the mouse [54] . All of these analyses, however, reported some diff erentially methylated regions (DMRs) between ES and iPS cells. Recent studies found that miPS cell lines retained the residual signatures of DNA methylation of the parental cells [55, 56] . Additionally, some of the hyper-methylated regions in hiPS cells are also hypermethylated in the original cells, meaning that an epigenetic memory is inherited during the reprogramming process through early passaging [57] . Parental cellrelated DMRs and incomplete promoter DNA methy lation contributed to aberrant gene expression profi les in iPS cells to some extent [58] . Th e other remaining DMRs appeared to be aberrantly methylated regions established in iPS cells during reprogramming that diff er from both the parental cells and the ES cells. Nishino and colleagues [57] compared methylation profi les of six hiPS cell lines and two hES cell lines and reported that approximately 60% of DMRs were inherited and 40% were iPS-specifi c. Interestingly, most aberrant DMRs were hyper-methylated in iPS cell lines [57, 59] . Lister and colleagues [60] also compared methylation profi les in fi ve hiPS cell lines and two hES cell lines and found that the hiPS cells shared megabase-scale DMRs proximal to centromeres and telomeres that display incomplete reprogramming of non-CpG methylation, and diff erences in CpG methylation and histone modifi cations in over a thousand DMRs between hES and hiPS cells. Although lots of studies have detected several DMRs shared between iPS and ES cells, no DMRs were found in all iPS cell lines. microRNAs (miRNAs), which are also epigenetically regulated, play critical roles in gene regulation by targeting specifi c mRNAs for degradation or by suppressing their translation. Several studies recently reported the presence of unique clusters of miRNAs, such as the human and mouse miR-302 cluster in ES and iPS cells [61, 62] . Th ese miRNAs enhance the transcrip tion factor-mediated reprogramming process (Table 1) . Furthermore, two independent groups generated human and mouse iPS cells by adding only miRNAs in the absence of any additional protein factors [63, 64] . Two reports have described a small number of diff erences in miRNA expression patterns between hiPS and hES cells [62, 65] , although our preliminary analysis showed that miR-372 and miR-373 are expressed at similar levels in both hiPS and hES cells and they were not detected in parental cells.
Changes of epigenetic profi les in iPS cells during culture
It is possible that iPS cells vary in their epigenetic profi les and degree of pluripotency due to diff erential levels of reprogramming. Nishino and colleagues [66] investigated the eff ect of continuous passaging on DNA methylation profi les of seven hiPS cell lines derived from fi ve cell types. Although de novo DMRs that diff er between hES and hiPS cells appeared at each passage, their number decreased and they disappeared with passaging; therefore, the total number of DMRs that diff er between ES and iPS cells decreased with passaging. Th us, continuous passaging of the iPS cells diminished the epigenetic diff er ences between iPS and ES cells, implying that iPS cells lose the characteristics inherited from the parental cells and develop to very closely resemble ES cells over time [66] . Th ey also confi rmed that the transgenes were silenced at each passage examined, indicating that the number of DMRs that diff ered between ES and iPS cells decreased during the transgene-independent phase. Th is is consistent with a study by Chin and colleagues [67] , who found that the gene expression profi le of hiPS cells appeared to become more similar to that of hES cells upon extended passaging. Although comprehensive DNA methylation profi les have recently been generated for hiPS cells, it seems harder to determine common DMR sites during iPS reprogramming. Th ere are three possible expla na tions for the many inconsistent results regarding iPS cell-specifi c DMRs: hiPS cells have only been analyzed at a single point of passage in almost all studies; inherited methylation from parental cells is non-synchronous and stochastic, much like aberrant methylation, rather than deterministic [66] ; and the aberrant hypermethylation at DMRs in iPS cells occurs 'stochastically' throughout the genome during passaging [66] .
Genetic changes during reprogramming and extended culture
Genomic stability is critical for the clinical use of hiPS cells. Th e occurrence of genetic changes in hES cells is now well known as well as that the karyotypic changes observed are nonrandom and commonly aff ect only a few chromosomes [68] . Recent studies revealed that the reprogramming process and subsequent culture of iPS cells in vitro can induce genetic changes. Th ree types of genomic abnormalities were seen: aberrations of somatic cell origin, aberrations present in early passages but not of apparent somatic cell origin, and aberrations acquired during passaging. Notably, the high incidence of chromosome 12 duplications observed by Mayshar and colleagues [69] caused signifi cant enrichment for cell cycle-related genes, such as NANOG and GDF3. Another study reported that regions close to pluripotency-associated genes were duplicated in multiple samples [70] . Selection during hiPS cell reprogramming, colony picking and subsequent culturing may be factors contributing to the accumulation of mutations.
Impact of epigenetic diff erences on pluripotency
One of the goals of using hiPS cells is to generate functional target cells for medical screening and therapeutic applications. For these applications, it must be evaluated thoroughly whether small DMRs among ES and iPS cells aff ect the competency, diff erentiation propensities, stability and safety of iPS cells. It remains to be elucidated how the degree of these diff er ences contributes to the variance in pluripotency among ES and iPS cells. Analysis of iPS cells obtained from mouse fi broblasts and hematopoietic and myogenic cells demonstrated that cellular origin infl uences the potential of miPS cells to diff erentiate into embryoid bodies and diff erent cell types in vitro. In a related study, Kim and colleagues [56] compared the ability to diff erentiate to blood lineages of iPS cells derived from fi broblasts, neural cells, hematopoietic cells and ES cells in the mouse system, and demonstrated consistent diff erences in blood-forming ability -that is, blood derivatives showed more robust hematopoiesis in vitro than neural derivatives. Th erefore, low-passage iPS cells derived from diff erent tissues harbor residual DNA methylation signatures characteristic of their somatic tissue of origin, which favors their diff erentiation along lineages related to the parental cell, while restricting alternative cell fates. Similarly, Miura and colleagues [71] demonstrated that diff erences in gene expression in miPS cells derived from diff erent types of parental cells result in variations in teratoma formation. Th ese studies demonstrate that repro gramming to generate iPS cells is a gradual process that modifi es epigenetic profi les beyond the acquisition of a pluripotent state.
Prediction for pluripotency and diff erentiation preference
Signifi cant variation has been also observed in the diff erentiation effi ciency of various hES cell lines [72] . Incomplete DNA methylation of somatic cells regulates the effi ciency of hiPS cell generation [58] , and selection of parental cell types infl uences the propensity for diff erentiation [73, 74] . Such diff erences must be better understood before hES and hiPS cell lines can be confidently used for translational research. To predict a cell line's propensity to diff erentiate into the three germ layers, Bock and colleagues [52] performed DNA methylation mapping by genome-scale bisulfi te sequencing and gene expression profi ling using microarrays and quantifi ed the propensity to form multiple lineages by utilizing a non-directed embryoid bodies formation assay and high-throughput transcript counting of 500 lineage marker genes in embryoid bodies using 20 hES cells lines and 12 hiPS cell lines over passages 15 to 30. Th ey bioinformatically integrated these genomic assays into a score card that measures the quality and utility of any human pluripotent cell line. Th e resulting lineage scorecard pinpoints quantitative diff erences among cell-linespecifi c diff erentiation propensities. For example, one hES cell line that received a high score for endoderm diff erentiation performed well in directed endoderm diff erentiation, and other hES cell lines that received high scores for neural lineage diff erentiation effi ciently diff erentiated into motor neurons. In addition, two hiPS lines that the scorecard predicted to have a low propensity to diff erentiate into the neural lineage were impaired in motor neuron-directed diff erentiation. On the other hand, other hiPS lines that the scorecard predicted to have a high propensity to diff erentiate into ectodermal and neural lineages were found to diff erentiate well into motor neurons. Th erefore, the scorecard can detect lineage-specifi c diff erences in the diff erentiation pro pensities of a given cell line [52] .
Functional assay for diff erentiated cells from iPS and ES cells
Although the propensity for diff erentiation could be predicted, it remains to be elucidated whether iPS cellderived cells are functionally and molecularly the same as ES cell-derived cells. To address this issue, two studies conducted functional assays comparing diff erentiated neural cells derived from iPS cells to those derived from ES cells by marker gene expression and action potential measurements [75, 76] . Th ere was some variation in effi ci ency and quantitative diff erences in motor neuron generation among the lines, but the treatment of neuroepithelial cells from pluripotent stem cells with retinoic acid and sonic hedgehog resulted in the generation of iPS and ES cell lines with a neuronal morphology that expressed TUJ1. In addition, electrophysiological recordings using whole-cell patch clamping showed inward and outward currents, and it was concluded that ES cell-and iPS cell-derived neurons are similarly functional at a physiological level. Th ese studies demonstrated that the temporal course and gene-expression pattern during neuroepithelial cell diff erentiation and production of functional neurons were nearly identical between ES and iPS cells, regardless of the reprogramming method, cellular origin, and diff erences between iPS and ES cells. Th ese fi ndings raise hopes of applying human iPS cells to the modeling of diseases and potential autologous cell transplantation. It is important to acquire scientifi c information on pluri potential stem cells for further applications, such as industrial and clinical uses. Pluripotent stem cells, including disease-specifi c stem cells, could be showcased with useful annotation data and the most appropriate cell lines could be selected (Figure 2 ).
Conclusion
Many issues have yet to be resolved before the results of stem cell research can benefi t the public in the form of medical treatments. In this review, we have discussed the substantial variation observed among pluripotent stem cells, including transcriptional and epigenetic profi les in the undiff erentiated state, the ability to diff erentiate into various types of cells, and the functional and molecular nature of embryoid body or stem cell-derived diff eren tiated cells. Th ese results suggest that most, but not all, iPS cell lines are indistinguishable from ES cell lines, even though there is a diff erence between the average ES cell and the average iPS cell. Th us, ES and iPS cells should not be regarded as one or two well-defi ned points in the cellular space but rather as two partially overlapping point clouds with inherent variability among both ES and iPS cell lines [52, 76] . Notably, human iPS cells seemed to be more variable than human ES cells. No single stem cell line may be equally powerful for deriving all cell types in vitro, implying that researchers would benefi t from identifying the best cell lines for each application. Furthermore, for clinical use in the future, it is important to use both ES and iPS cells in research, and to standardize reprogramming methods, culture equipment and techniques and to optimize diff erentiation methods and evaluate the functions and tumorigenicity of diff erentiated cells. Workfl ow for human iPS cell applications. 1. Selection: choosing donor parent tissue considering accessibility, effi ciency of reprogramming, and diff erential propensity. It would be useful to evaluate the expression of somatic memory genes, such as C9orf64, which reduces the effi ciency of induced pluripotent stem (iPS) cell generation [58] . 2. Showcasing/evaluation: provides annotated information on reprogramming methods, culture conditions, physical data on stem cells, and global data on DNA methylation, transcription and microRNAs (miRNAs). It is very informative to integrate the genetic and epigenetic and biological data, such as diff erential propensity [52, 76] . 3. Application: using annotation data, we can select the most appropriate iPS cell lines for our applications. Various hiPS cell lines (shown as diff erently shaded spheres) would be listed before further processing of the application. Valid cell lines (colored purple and blue) could be functionally and molecularly selected for appropriate applications, such as cell replacement therapy and/or drug screening.
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